Arabic Arabic English English French French German German
dark

Experimental drug development approach points to better targeted therapies for treatment-resistant leukemia

New research from Johns Hopkins Kimmel Cancer Center investigators shows why some drugs in clinical trials for treating a form of acute myeloid leukemia (AML) often fail and demonstrates a way to restore their effectiveness. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Schizophrenia tied to higher risk for severe COVID-19

Next Post

Tens of thousands of New York health care workers could lose jobs as soon as today over vaccine

Related Posts
Total
0
Share